| Complete Therapy Usa Inc. | |
|
2627 Ne 203rd St, Suite 110, Aventura, FL 33180-1900 | |
| (305) 466-1388 | |
| (305) 466-9200 |
| Full Name | Complete Therapy Usa Inc. |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 2627 Ne 203rd St, Aventura, Florida |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598826133 | NPI | - | NPPES |
| 888726800 | Medicaid | FL | |
| 6485550001 | Other | FL | MEDICARE DME |
| X1524 | Other | FL | MEDICARE IDENTIFICATION NUMBER |
| 1598826133 | Other | FL | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (Florida) | Primary |
| 225X00000X | Occupational Therapist | (Florida) | Secondary |
| Provider Name | Judith B Neiman |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1265402101 PECOS PAC ID: 3375441926 Enrollment ID: I20060113000109 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Yolanda Colon |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1063721405 PECOS PAC ID: 9335304138 Enrollment ID: I20120628000618 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Stephanie L Hill |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659559425 PECOS PAC ID: 5799030250 Enrollment ID: I20180625001813 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Guisselle A Paredes |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1841787215 PECOS PAC ID: 7517205917 Enrollment ID: I20190327002196 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Merin V Kurian |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1134703622 PECOS PAC ID: 3779984083 Enrollment ID: I20210624000696 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Marvin L Posas |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1417295841 PECOS PAC ID: 1951783992 Enrollment ID: I20220808000890 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Eileen D Groll |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1932839883 PECOS PAC ID: 6002283306 Enrollment ID: I20221028002039 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Jessica Golan |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1558898668 PECOS PAC ID: 7214302124 Enrollment ID: I20230406001583 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Seasia M Catena |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1184300840 PECOS PAC ID: 2466812995 Enrollment ID: I20230717000501 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Rafat Hamdan |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1033899158 PECOS PAC ID: 8022470418 Enrollment ID: I20230816004317 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Jenna Eljaua |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336821297 PECOS PAC ID: 3678937505 Enrollment ID: I20230912000591 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Shelley Anne M Williams |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1710769815 PECOS PAC ID: 1658727318 Enrollment ID: I20231101000720 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Ana Y Silva Bazanta |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1538933387 PECOS PAC ID: 1850744970 Enrollment ID: I20240125000735 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Provider Name | Hemdat Bar |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1780453753 PECOS PAC ID: 2264878602 Enrollment ID: I20240307004330 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Complete Therapy Usa Inc. 2627 Ne 203rd St, Suite 110, Aventura, FL 33180-1900 Ph: (305) 466-1388 | Complete Therapy Usa Inc. 2627 Ne 203rd St, Suite 110, Aventura, FL 33180-1900 Ph: (305) 466-1388 |
News Archive
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation long enough to respond to and stop virus infection.
Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn't been possible for people with phenylketonuria (PKU).
Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
› Verified 8 days ago
Mrs. Carrie A Schauer, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 20900 Biscayne Blvd, Aventura, FL 33180 Phone: 305-937-5802 | |
Preferred Physical Therapy Associates, Inc. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 18859 Biscayne Blvd, Aventura, FL 33180 Phone: 561-544-0800 Fax: 561-395-6995 | |
Mrs. Leslie Leibowitz, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6000 Island Blvd, # 2202, Aventura, FL 33160 Phone: 305-931-8900 Fax: 954-583-7388 | |
Rafat Hamdan, Physical Therapist Medicare: Medicare Enrolled Practice Location: 2627 Ne 203rd St Ste 110, Aventura, FL 33180 Phone: 305-466-1388 Fax: 305-466-9200 | |
Alejandro Diaz, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 16249 Biscayne Blvd, Aventura, FL 33160 Phone: 305-405-0400 Fax: 305-405-0415 | |
Rohit Gaikwad, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 21110 Biscayne Blvd, 205, Aventura, FL 33180 Phone: 786-272-5697 | |
Sara Kae Santana, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 16249 Biscayne Blvd, Aventura, FL 33160 Phone: 305-405-0400 |